Literature DB >> 21585657

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

John E Weldon1, Ira Pastan.   

Abstract

Pseudomonas exotoxin A (PE) is a highly toxic protein secreted by the opportunistic pathogen Pseudomonas aeruginosa. The modular structure and corresponding mechanism of action of PE make it amenable to extensive modifications that can redirect its potent cytotoxicity from disease to a therapeutic function. In combination with a variety of artificial targeting elements, such as receptor ligands and antibody fragments, PE becomes a selective agent for the elimination of specific cell populations. This review summarizes our current understanding of PE, its intoxication pathway, and the ongoing efforts to convert this toxin into a treatment for cancer. Journal compilation
© 2011 FEBS. No claim to original US government works.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21585657      PMCID： PMC3179548          DOI： 10.1111/j.1742-4658.2011.08182.x

Source DB:  PubMed          Journal:  FEBS J        ISSN： 1742-464X            Impact factor:   5.622


  156 in total

1.  Selective translocation of the A chain of diphtheria toxin across the membrane of purified endosomes.

Authors:  B Beaumelle; L Bensammar; A Bienvenüe
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Rapid turnover of mcl-1 couples translation to cell survival and apoptosis.

Authors:  Kenneth W Adams; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2007-01-02       Impact factor: 5.157

3.  Protein-disulfide isomerase-mediated reduction of the A subunit of cholera toxin in a human intestinal cell line.

Authors:  P A Orlandi
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

4.  Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.

Authors:  K Selvaggi; E A Saria; R Schwartz; D R Vlock; S Ackerman; N Wedel; J M Kirkwood; H Jones; M S Ernstoff
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-04

5.  Characterization of the endogenous ADP-ribosylation of wild-type and mutant elongation factor 2 in eukaryotic cells.

Authors:  J L Fendrick; W J Iglewski; J M Moehring; T J Moehring
Journal:  Eur J Biochem       Date:  1992-04-01

6.  Characterization of a cellular protease that cleaves Pseudomonas exotoxin.

Authors:  C Fryling; M Ogata; D FitzGerald
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

Review 7.  Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism.

Authors:  B A Wilson; R J Collier
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.737

8.  Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis.

Authors:  D J FitzGerald; R Padmanabhan; I Pastan; M C Willingham
Journal:  Cell       Date:  1983-02       Impact factor: 66.850

9.  A molecular specificity code for the three mammalian KDEL receptors.

Authors:  Irina Raykhel; Heli Alanen; Kirsi Salo; Jaana Jurvansuu; Van Dat Nguyen; Maria Latva-Ranta; Lloyd Ruddock
Journal:  J Cell Biol       Date:  2007-12-17       Impact factor: 10.539

10.  Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.

Authors:  R J Kreitman; I Pastan
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.766
View more
  107 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Neural stem cell therapy for cancer.

Authors:  Juli Rodriguez Bagó; Kevin T Sheets; Shawn D Hingtgen
Journal:  Methods       Date:  2015-08-24       Impact factor: 3.608

3.  NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Johannes T Wessels; Agnes Schröder; Michael J May; Dietmar Vestweber; Jochen Zwerina; Klaus Warnatz; Falk Nimmerjahn; Georg Schett; Stefan Dübel; Reinhard Edmund Voll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

Review 4.  Novel bacterial ADP-ribosylating toxins: structure and function.

Authors:  Nathan C Simon; Klaus Aktories; Joseph T Barbieri
Journal:  Nat Rev Microbiol       Date:  2014-07-14       Impact factor: 60.633

Review 5.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

6.  Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.

Authors:  Ronit Mazor; Devorah Crown; Selamawit Addissie; Youjin Jang; Gilad Kaplan; Ira Pastan
Journal:  Cell Mol Immunol       Date:  2015-10-19       Impact factor: 11.530

7.  Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Authors:  A Antignani; D Segal; N Simon; R J Kreitman; D Huang; D J FitzGerald
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

8.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

9.  Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

Authors:  Alexander N Wein; Shihui Liu; Yi Zhang; Andrew T McKenzie; Stephen H Leppla
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

10.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.